Zydus Cadila has received the final approval from the USFDA to market Nystatin and Triamcinolone Acetonide Ointment USP, (US RLD -Mycolog-II Ointment), 100,000 units/gram and 1 mg/gram. It will be manufactured at the group's Topical manufacturing facility at Ahmedabad.
It is used to treat fungal skin infections. This product contains nystatin, an anti-fungal drug that works by stopping the growth of fungus. It also contains triamcinolone, an anti-inflammatory corticosteroid that works by reducing swelling, itching, and redness.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
